HighVista Strategies’s Ocular Therapeutix OCUL Stock Holding History

HighVista Strategies’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.01M	Sell	408,534 -33,039	-7%	-$299K	0.91%	35
2026 Q1	$3.74M	Buy	441,573 +97,506	+28%	+$929K	1.03%	23
2025 Q4	$4.18M	Buy	344,067 +237,456	+223%	+$2.88M	1.08%	30
2025 Q3	$1.25M	Buy	106,611 +17,735	+20%	+$212K	0.31%	105
2025 Q2	$825K	Buy	88,876 +3,635	+4%	+$28.5K	0.3%	114
2025 Q1	$625K	Hold	85,241	–	–	0.24%	120
2024 Q4	$728K	Buy	85,241 +20,214	+31%	+$197K	0.27%	113
2024 Q3	$566K	Buy	65,027 +3,168	+5%	+$26.1K	0.2%	119
2024 Q2	$423K	Buy	+61,859	New	+$382K	0.15%	119
2022 Q1	–	Sell	-58,965	Closed	-$411K	–	93
2021 Q4	$411K	Sell	58,965 -10,097	-15%	-$78.4K	0.33%	67
2021 Q3	$691K	Buy	69,062 +7,423	+12%	+$83.4K	0.46%	62
2021 Q2	$875K	Buy	+61,639	New	+$937K	0.62%	31

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HighVista Strategies's OCUL Position: Q2 2026 in Review

HighVista Strategies reduced its Ocular Therapeutix (OCUL) stake by 7.5% in Q2 2026, selling an estimated $299K and leaving 408,534 shares worth $4.01M. The position accounts for 0.91% of the portfolio, ranked #35.

HighVista Strategies first reported a position in OCUL in Q2 2021 and has held it in 12 quarters since. The position peaked at $4.18M in Q4 2025. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

HighVista Strategies held 408,534 shares of Ocular Therapeutix worth $4.01M as of Q2 2026.
HighVista Strategies sold 33,039 Ocular Therapeutix shares in Q2 2026, an estimated $299K.
Ocular Therapeutix made up 0.91% of HighVista Strategies's portfolio in Q2 2026, its #35 holding.
HighVista Strategies first reported a position in Ocular Therapeutix in Q2 2021 and has held it in 12 quarters since.
HighVista Strategies's Ocular Therapeutix position peaked at $4.18M in Q4 2025.
263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.